Compare Stocks: LEGN, EXEL, BMRN, and ARWR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$85.59 -1.9%	$80.89	$18.14 ▼ $95.49	$12.06B	1.27	2.40 million shs	1.10 million shs
BMRN BioMarin Pharmaceutical	$68.53 -2.4%	$59.35	$49.26 ▼ $70.98	$13.27B	0.24	2.10 million shs	2.31 million shs
EXEL Exelixis	$50.61 +0.5%	$54.25	$33.76 ▼ $57.57	$12.54B	0.44	2.72 million shs	1.95 million shs
LEGN Legend Biotech	$20.27 -1.8%	$26.10	$16.24 ▼ $38.35	$3.76B	0.37	2.52 million shs	1.97 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-2.23%	+0.39%	+17.73%	+9.49%	+390.17%
BMRN BioMarin Pharmaceutical	+0.99%	+17.24%	+18.65%	+31.93%	+23.53%
EXEL Exelixis	-1.85%	-11.15%	-10.10%	-1.41%	+32.75%
LEGN Legend Biotech	-5.41%	+8.40%	-19.81%	-27.80%	-44.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$85.59 -1.9%	$80.89	$18.14 ▼ $95.49	$12.06B	1.27	2.40 million shs	1.10 million shs
BMRN BioMarin Pharmaceutical	$68.53 -2.4%	$59.35	$49.26 ▼ $70.98	$13.27B	0.24	2.10 million shs	2.31 million shs
EXEL Exelixis	$50.61 +0.5%	$54.25	$33.76 ▼ $57.57	$12.54B	0.44	2.72 million shs	1.95 million shs
LEGN Legend Biotech	$20.27 -1.8%	$26.10	$16.24 ▼ $38.35	$3.76B	0.37	2.52 million shs	1.97 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-2.23%	+0.39%	+17.73%	+9.49%	+390.17%
BMRN BioMarin Pharmaceutical	+0.99%	+17.24%	+18.65%	+31.93%	+23.53%
EXEL Exelixis	-1.85%	-11.15%	-10.10%	-1.41%	+32.75%
LEGN Legend Biotech	-5.41%	+8.40%	-19.81%	-27.80%	-44.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.62	Moderate Buy	$97.33	13.72% Upside
BMRN BioMarin Pharmaceutical	2.70	Moderate Buy	$88.00	28.41% Upside
EXEL Exelixis	2.32	Hold	$49.79	-1.63% Downside
LEGN Legend Biotech	2.47	Hold	$52.29	157.95% Upside

Current Analyst Ratings Breakdown

Latest LEGN, EXEL, BMRN, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $49.00
8/12/2026	LEGN Legend Biotech	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$75.00 ➝ $40.00
8/12/2026	LEGN Legend Biotech	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$80.00 ➝ $78.00
8/12/2026	LEGN Legend Biotech	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$29.00 ➝ $24.00
8/12/2026	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$59.00 ➝ $58.00
8/12/2026	LEGN Legend Biotech	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$75.00 ➝ $40.00
8/11/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
8/11/2026	EXEL Exelixis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B) ➝ Buy (A-)
8/10/2026	BMRN BioMarin Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$111.00 ➝ $114.00
8/7/2026	BMRN BioMarin Pharmaceutical	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$95.00 ➝ $97.00
8/7/2026	BMRN BioMarin Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$119.00 ➝ $124.00

(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$669.50M	18.01	$0.11 per share	747.40	$3.31 per share	25.86
BMRN BioMarin Pharmaceutical	$3.22B	4.12	$2.81 per share	24.38	$32.66 per share	2.10
EXEL Exelixis	$2.32B	5.40	$2.98 per share	16.96	$7.44 per share	6.80
LEGN Legend Biotech	$1.03B	3.66	N/A	N/A	$5.43 per share	3.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	N/A
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	185.22	12.17	0.48	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	15.92	13.79	1.55	35.33%	42.17%	31.76%	N/A
LEGN Legend Biotech	-$296.80M	-$0.68	N/A	12.99	N/A	-7.21%	-9.23%	-5.45%	N/A

Latest LEGN, EXEL, BMRN, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million
5/13/2026	Q1 2026	LEGN Legend Biotech	-$0.02	-$0.03	-$0.01	-$0.30	$306.51 million	$305.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
EXEL Exelixis	N/A	3.46	3.38
LEGN Legend Biotech	N/A	2.13	2.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BMRN BioMarin Pharmaceutical	98.71%
EXEL Exelixis	85.27%
LEGN Legend Biotech	70.89%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
BMRN BioMarin Pharmaceutical	0.68%
EXEL Exelixis	2.60%
LEGN Legend Biotech	0.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	140.86 million	135.79 million	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
LEGN Legend Biotech	2,965	185.74 million	185.70 million	Optionable

LEGN, EXEL, BMRN, and ARWR Headlines

Recent News About These Companies

Legend Biotech (LEGN) Receives a Buy from Morgan Stanley

4 hours ago | theglobeandmail.com

Legend Biotech Could See Pressures From Competition, CEO Transition, Oppenheimer Says

4 hours ago | finance.yahoo.com

Legend Biotech (NASDAQ:LEGN) Shares Gap Up on Better-Than-Expected Earnings

August 13 at 1:52 AM | americanbankingnews.com

Former Legend Biotech chief to lead newco builder K2 Therapeutics

August 12 at 6:09 PM | thepharmaletter.comT

Legend Biotech downgraded at Oppenheimer on CEO exit, competition

August 12 at 6:09 PM | seekingalpha.com

Legend Biotech (NASDAQ:LEGN) Trading Down 5.3% Following Analyst Downgrade

August 12 at 12:19 PM | marketbeat.com

TD Cowen Cuts Legend Biotech (NASDAQ:LEGN) Price Target to $24.00

August 12 at 11:29 AM | marketbeat.com

Legend Biotech (NASDAQ:LEGN) Given New $58.00 Price Target at Royal Bank Of Canada

August 12 at 10:17 AM | marketbeat.com

Legend Biotech (NASDAQ:LEGN) Receives "Market Perform" Rating from Oppenheimer

August 12 at 10:05 AM | marketbeat.com

Legend's Pipeline Is Starting To Matter

August 12 at 7:44 AM | seekingalpha.com

Analysts Set Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Price Target at $55.29

August 12 at 3:30 AM | americanbankingnews.com

Legend Biotech (LEGN) Earnings: What to Watch When Carvykti Reports

August 11 at 12:52 AM | 247wallst.com

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

August 11 at 12:52 AM | markets.businessinsider.com

Legend Biotech (NASDAQ:LEGN): What Could Today’s Update Reveal About Cell-Therapy Demand And Manufacturing?

August 11 at 12:52 AM | kalkinemedia.comK

Legend Biotech shares rise 5% as Q2 earnings and revenue beat estimates

August 11 at 12:52 AM | msn.com

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript

August 11 at 12:52 AM | finance.yahoo.com

Legend Biotech Corporation 2026 Q2 - Results - Earnings Call Presentation

August 11 at 5:31 PM | seekingalpha.com

Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript

August 11 at 3:00 PM | seekingalpha.com

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus

August 11 at 1:00 PM | 247wallst.com

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus

August 11 at 12:50 PM | 247wallst.com

Legend Biotech (NASDAQ:LEGN) Announces Earnings Results

August 11 at 10:40 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN, EXEL, BMRN, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$85.59 -1.66 (-1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$85.59 0.00 (0.00%)

As of 04:58 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

BioMarin Pharmaceutical NASDAQ:BMRN

$68.53 -1.71 (-2.43%)

Closing price 04:00 PM Eastern

Extended Trading

$69.50 +0.97 (+1.41%)

As of 05:11 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis NASDAQ:EXEL

$50.61 +0.23 (+0.46%)

Closing price 04:00 PM Eastern

Extended Trading

$50.64 +0.02 (+0.05%)

As of 06:00 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Legend Biotech NASDAQ:LEGN

$20.27 -0.38 (-1.84%)

Closing price 04:00 PM Eastern

Extended Trading

$20.38 +0.11 (+0.54%)

As of 05:51 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LEGN, EXEL, BMRN, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LEGN, EXEL, BMRN, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LEGN, EXEL, BMRN, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN, EXEL, BMRN, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Legend Biotech NASDAQ:LEGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LEGN, EXEL, BMRN, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LEGN, EXEL, BMRN, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LEGN, EXEL, BMRN, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN, EXEL, BMRN, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Legend Biotech NASDAQ:LEGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools